Canagliflozin
Canagliflozin (CAS 842133-18-0) is a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), a transporter responsible for renal glucose reabsorption. By inhibiting SGLT2 activity, Canagliflozin decreases renal glucose reabsorption, resulting in increased urinary glucose excretion. In CHO cells expressing human, rat, or mouse SGLT2, Canagliflozin potently inhibits sodium-dependent glucose uptake, with IC50 values of 4.4, 3.7, and 2.0 nM, respectively. Animal studies using db/db mice and Zucker diabetic fatty (ZDF) rats demonstrate dose-dependent reductions in blood glucose, as well as decreased respiratory exchange ratio and body weight. Canagliflozin is suitable for in vivo research through oral administration.
- 1. Mayra Trentin-Sonoda, Véronique Cheff, et al. "Sex-dependent effects of Canagliflozin on kidney protection in mice with combined hypertension-type 1 diabetes." PLoS One. 2023 Dec 6;18(12):e0295284. PMID: 38055691
- 2. Michael Gamal Fawzy, Mohamed A Said, et al. "Valuation of environmental influence of recently invented high‐performance liquid chromatographic method for hypoglycemic mixtures of gliflozins and metformin in the presence of melamine impurities: Application of molecular modeling simulation approach." J Sep Sci. 2023 Jul 23;e2300267. PMID: 37485588
- 3. Bahia Abbas Moussa, Marianne Alphonse Mahrouse, et al. "Different resolution techniques for management of overlapped spectra: Application for the determination of novel co-formulated hypoglycemic drugs in their combined pharmaceutical dosage form." Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy Available online 20 June 2018.
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 444.52 |
| Cas No. | 842133-18-0 |
| Formula | C24H25FO5S |
| Synonyms | JNJ 24831754ZAE; JNJ 28431754; JNJ 28431754AAA; TA 7284 |
| Solubility | ≥22.25 mg/mL in DMSO; insoluble in H2O; ≥49.5 mg/mL in EtOH |
| Chemical Name | (2S,3R,4R,5S,6R)-2-[3-[[5-(4-fluorophenyl)thiophen-2-yl]methyl]-4-methylphenyl]-6-(hydroxymethyl)oxane-3,4,5-triol |
| SDF | Download SDF |
| Canonical SMILES | CC1=C(C=C(C=C1)C2C(C(C(C(O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Cell experiment:[1] | |
|
Cell lines |
Rat skeletal muscle cell line L6 |
|
Reaction Conditions |
10 μM canagliflozin for 15 min incubation |
|
Applications |
At 10 μM, canagliflozin inhibited the facilitative (non-Na+-linked) glucose transporter-mediated 2-deoxy-glucose uptake in L6 myoblasts by less than 50%. |
| Animal experiment:[1] | |
|
Animal models |
Male C57BL/ksj-db/db hyperglycemic mice |
|
Dosage form |
0.1, 1 and 10 mg/kg Administrated via oral gavage |
|
Applications |
In db/db mice, single doses of canagliflozin dose-dependently reduced non-fasting blood glucose (BG) concentrations. The onset of the BG-lowering effect after a single dose was rapid, and BG levels in canagliflozin-treated mice (at 1 and 10 mg/kg doses) were significantly different from those of vehicle-treated mice at 1 hour after treatment. This antihyperglycemic effect reached its peak at 6 hours. |
|
Note |
The technical data provided above is for reference only. |
|
References: 1. Liang Y, Arakawa K, Ueta K, et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One, 2012, 7(2): e30555. |
|
| Targets | hSGLT2 | rSGLT2 | mSGLT2 | |||
| IC50 | 4.4 nM | 3.7 nM | 2 nM |
Quality Control & MSDS
- View current batch:
Chemical structure
Related Biological Data
Related Biological Data
